GLP-1 analog raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-05. Anything still debated is marked as such rather than presented as settled.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
== Nutrition == Felines are carnivores and have adapted to animal-based diets and low carbohydrate inclusion. Kittens belong to the growth life stage and have high energy and protein requirements. When feeding a kitten, it is often recommended to use highly digestible ingredients and a variety of components to support development and ensure a healthy adult cat. In North America, diets certified by the Association of American Feed Control Officials (AAFCO) are accepted as adequate nutrition; therefore, kitten diets should be AAFCO-approved to guarantee complete supplementation. Key components of the diet are high fat content to meet caloric requirements of growth, high protein to promote muscle growth, and supplementation of certain nutrients such as docosahexaenoic acid to support brain development and the optimization of cognition.
The same is true for vessels in air: a dirigible that weighs 100 tons needs to displace 100 tons of air. If it displaces more, it rises; if it displaces less, it falls. If the dirigible displaces exactly its weight, it hovers at a constant altitude. While they are related to it, the principle of flotation and the concept that a submerged object displaces a volume of fluid equal to its own volume are not Archimedes' principle. Archimedes' principle, as stated above, equates the buoyant force to the weight of the fluid displaced. One common point of confusion regarding Archimedes' principle is the meaning of displaced volume. Common demonstrations involve measuring the rise in water level when an object floats on the surface in order to calculate the displaced water. This measurement approach fails with a buoyant submerged object because the rise in the water level is directly related to the volume of the object and not the mass (except if the effective density of the object equals exactly the fluid density).
The three-member tribunal was unanimous in its decision. The tribunal repeated prior criticisms of the governance of the Essendon's supplements program, which had been seen in the ASADA interim report and the Switkowski report. As a result of the verdict, the provisional suspensions on the players were lifted, and all affected players were eligible to play in Round 1. ASADA and the AFL were given a window of 21 days to appeal the decision. The verdict was handed down in private, and few other details about the reasons for the decision were released.
black tar heroin cannabis datura and other Solanaceae (formerly smoked to treat asthma) opium salvia divinorum tobacco possibly other plants (see the section below) Substances (also not necessarily psychoactive plants smoked within them):
Sources: en.wikipedia.org
The Weird Sisters in Shakespeare's Macbeth used the fur of a bat in their brew. In Western culture, the bat is often a symbol of the night and its foreboding nature. The bat is a primary animal associated with fictional characters of the night, both villainous vampires, such as Count Dracula and the earlier Varney the Vampire, and heroes, such as the DC Comics character Batman. The bat is sometimes used as a heraldic symbol in many European countries, including France, Belgium, Germany, Spain and the UK. They have also been used as symbols in the militaries of the UK, US and Israel. Three US states have an official state bat. Texas and Oklahoma are represented by the Mexican free-tailed bat, while Virginia is represented by the Virginia big-eared bat (Corynorhinus townsendii virginianus).
While menstruation is heavily associated with human females, and they have the most pronounced menstruation, it is also typical of ape relatives and monkeys. Female macaques menstruate, with a cycle length over the course of a lifetime that is comparable to that of female humans. Estrogens and progestogens in the menstrual cycles and during premenarche and postmenopause are also similar in female humans and macaques; however, only in macaques does keratinization of the epithelium occur during the follicular phase. The vaginal pH of macaques also differs, with near-neutral to slightly alkaline median values and is widely variable, which may be due to its lack of lactobacilli in the vaginal flora. This is one reason why, although macaques are used for studying HIV transmission and testing microbicides, animal models are not often used in the study of sexually transmitted infections, such as trichomoniasis. Another is that such conditions' causes are inextricably bound to humans' genetic makeup, making results from other species difficult to apply to humans.
== Scaffolds == A scaffold or matrix serves as a temporary supporting structure (extracellular matrix), the initial architecture, on which the cells can grow three-dimensionally into the desired tissue. A scaffold must provide the environment needed for cellular growth and differentiation; it must provide the strength to withstand mechanical stress and guide their growth. Moreover, scaffolds should be biodegradable and degrade at the same rate as the tissue regenerates to be optimally replaced by the host tissue. There are numerous scaffolds to choose from and when choosing a scaffold biocompatibility, porosity and stability should also be held into account. Available scaffolds for oral mucosa tissue engineering are:
In the United States, when plutonium-238 became available for non-military uses, numerous applications were proposed and tested, including the cardiac pacemaker program that began on June 1, 1966, in conjunction with NUMEC. The last of these units was implanted in 1988, as lithium-powered pacemakers, which had an expected lifespan of 10 or more years without the disadvantages of radiation concerns and regulatory hurdles, made these units obsolete. As of 2007, there were nine living people with nuclear-powered pacemakers in the United States, out of an original 139 recipients. When these individuals die, the pacemaker is supposed to be removed and shipped to Los Alamos where the plutonium will be recovered. In a letter to the New England Journal of Medicine discussing a woman who received a Numec NU-5 decades ago that is continuously operating, despite an original $5,000 price tag equivalent to $36,263 in 2025 dollars, the follow-up costs have been about $19,000 ($29,502 in 2025 dollars) compared with $55,000 ($85,400 in 2025 dollars) for a battery-powered pacemaker. Another nuclear powered pacemaker was the Medtronics “Laurens-Alcatel Model 9000”. Approximately 1600 nuclear-powered cardiac pacemakers and/or battery assemblies have been located across the United States, and are eligible for recovery by the Off-Site Source Recovery Project (OSRP) Team at Los Alamos National Laboratory (LANL).
Technology companies have built electricity and artificial intelligence infrastructure to facilitate the AI boom of the 2020s. A 2025 report from the consulting firm McKinsey & Company estimated that by 2030, $2.7 trillion would be invested into AI infrastructure and data centres in the US, surpassing World War II's Manhattan Project every month. In January 2024, the International Energy Agency (IEA) released Electricity 2024, Analysis and Forecast to 2026. This is the first IEA report to make projections for data centres and power consumption by AI and cryptocurrency. The report states that power demand for these uses might double by 2026, with the additional power consumption equaling that of Japan. Power consumption by AI is responsible for an increase in fossil fuel use, and has delayed closings of obsolete, carbon-emitting coal energy facilities. A ChatGPT search involves 10 times as much electrical energy as a Google search. A 2024 Goldman Sachs research paper, AI Data Centers and the Coming US Power Demand Surge, found "US power demand (is) likely to experience growth not seen in a generation...." and forecasts that, by 2030, US data centres will consume 8% of US power, as opposed to 3% in 2022, presaging growth for the electrical power generation industry by a variety of means. Data centres' need for more and more electrical power is such that they might max out the electrical grid. The Big Tech companies counter that AI can be used to maximise the utilisation of the grid by all.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.